eIF2C2 Inhibitors

Common eIF2C2 Inhibitors include, but are not limited to Etoposide (VP-16) CAS 33419-42-0, Fluorouracil CAS 51-21-8, Bortezomib CAS 179324-69-7, Cisplatin CAS 15663-27-1 and Actinomycin D CAS 50-76-0.

Eukaryotic translation initiation factor 2C2 (eIF2C2), also widely recognized as Argonaute 2 (Ago2), plays a pivotal role in the RNA-induced silencing complex (RISC) within cells. The RISC is central to the RNA interference (RNAi) pathway, a mechanism responsible for post-transcriptional gene silencing in a sequence-specific manner. eIF2C2/Ago2 emerges as the primary effector protein in this complex, endowed with endonuclease activity, enabling it to cleave target mRNA. Beyond its endonucleolytic capabilities, eIF2C2/Ago2 also functions as a platform, binding to small RNAs, such as microRNAs (miRNAs) and small interfering RNAs (siRNAs). These small RNAs act as guides, directing the eIF2C2/Ago2-containing RISC to complementary sequences on target mRNAs, leading to their subsequent degradation or translational repression.

Inhibitors targeting eIF2C2/Ago2 are molecules designed to modulate the function of eIF2C2/Ago2, impeding its endonucleolytic activity, interaction with small RNAs, or its association with other components of the RISC. Given eIF2C2/Ago2's fundamental role in the RNAi pathway, these inhibitors could have profound effects on post-transcriptional gene regulation. The precise molecular mechanism through which these inhibitors exert their effects can vary. Some might directly bind to eIF2C2/Ago2, altering its conformation and subsequently its functionality. Others might interfere with its interaction with small RNAs, disrupting the RNAi process at its foundational level. The study of eIF2C2/Ago2 inhibitors offers an avenue to understand the intricacies of the RNAi pathway better, elucidating the myriad of molecular interactions that coalesce to regulate gene expression post-transcriptionally. The chemical landscape of these inhibitors remains a dynamic and evolving field, continually expanding as novel compounds are synthesized and characterized.